Liaoning Chengda Biotechnology Co

Liaoning Chengda Biotechnology Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Liaoning Chengda Biotechnology Co (688739.SS) as of Oct 17, 2026 is 196.98 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 589.09 M CNY — a change of -66.56% (lower).

EBITDA

196.98 MCNY

YoY

-66.56%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Liaoning Chengda Biotechnology Co is 2025 196.98 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Liaoning Chengda Biotechnology Co was 2024 589.09 M CNY. It decreases by -66.56% lower compared to the previous year.

The Liaoning Chengda Biotechnology Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
728.20 M CNY
Jan 1, 2019
838.43 M CNY
Jan 1, 2020
1.04 B CNY
Jan 1, 2021
1.13 B CNY
Jan 1, 2022
880.15 M CNY
Jan 1, 2023
701.42 M CNY
Jan 1, 2024
589.09 M CNY
Jan 1, 2025
196.98 M CNY
The Liaoning Chengda Biotechnology Co EBITDA history
YEAREBITDAYoY
196.98 MCNY-66.56%
589.09 MCNY-16.01%
701.42 MCNY-20.31%
880.15 MCNY-22.05%
1.13 BCNY+8.46%
1.04 BCNY+24.18%
838.43 MCNY+15.14%
728.20 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Liaoning Chengda Biotechnology Co Stock analysis

What does Liaoning Chengda Biotechnology Co do? Liaoning Chengda Biotechnology Co., Ltd. is a prominent entity in the health care sector, specifically operating within the biotechnology industry. Headquartered in Shenyang, located in the Liaoning province of China, the company has established itself as a significant player in the development and commercialization of medical solutions. As of the latest available data, the organization employs a workforce of 1,663 full-time employees, reflecting its substantial operational scale and commitment to research and development activities. The company's primary business focus revolves around the research, development, manufacturing, and sale of vaccines, addressing critical public health needs through innovative biological products. The firm's product portfolio is centered on essential immunizations, including the rabies vaccine for human use and the freeze-dried rabies vaccine for human use. Additionally, the company produces vaccines targeting Japanese encephalitis, specifically offering the inactivated Japanese encephalitis vaccine for human use and the freeze-dried encephalitis inactivated vaccine. These products are marketed under two distinct brand names: Chengda Suda and Chengda Libao, which serve to differentiate the various offerings within the company's lineup. The strategic emphasis on these specific vaccines highlights the company's dedication to combating infectious diseases that pose significant risks to human health. Liaoning Chengda Biotechnology Co., Ltd. entered the public markets through an initial public offering on October 28, 2021, marking a significant milestone in its corporate history and providing it with greater access to capital for future growth and expansion. The company's official online presence can be found at http://www.cdbio.cn, where stakeholders and interested parties can access further information regarding its operations and developments. With its strong foundation in Shenyang and a dedicated team of professionals, the company continues to contribute to the global health care landscape by delivering high-quality vaccine solutions. The combination of its extensive employee base, specialized product range, and public market listing underscores its role as a key contributor to the biotechnology sector in China and beyond. Liaoning Chengda Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Liaoning Chengda Biotechnology Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Liaoning Chengda Biotechnology Co is 196.98 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Liaoning Chengda Biotechnology Co changed from 589.09 M CNY to 196.98 M CNY, representing a -66.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Liaoning Chengda Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Liaoning Chengda Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Liaoning Chengda Biotechnology Co

All Key Metrics — Liaoning Chengda Biotechnology Co